Laekna (HKSE:02105) NonCurrent Deferred Liabilities : HK$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Laekna's non-current deferred liabilities for the quarter that ended in Dec. 2024 was HK$0.00 Mil.

Laekna NonCurrent Deferred Liabilities Historical Data

The historical data trend for Laekna's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna NonCurrent Deferred Liabilities Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

NonCurrent Deferred Liabilities

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

Laekna NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Laekna's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Futu Trustee Limited	2301 Trustee
Lu Chris Xiangyang	2501 Other
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Laekna Wonderland Limited	2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc.	2101 Beneficial owner
Liu Zeng	2201 Interest of corporation controlled by you
Ealex Llc	2101 Beneficial owner

Laekna Headlines

No Headlines